Although cytokine responses were similar overall among all MS treatment cohorts, a significant increase in IFN-γ+ CD8+ T cells was observed in patients receiving RTX and OCR and in TNF-α+ CD8+ T cells in patients treated with S1P receptor modulators and RTX, compared with HCs (Figure 4F). The gene discussed is CD8A; the disease is myeloid sarcoma.